{"nctId":"NCT02006641","briefTitle":"Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil","startDateStruct":{"date":"2014-02"},"conditions":["Alzheimer's Disease"],"count":858,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Idalopirdine 10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Idalopirdine"]},{"label":"Idalopirdine 30 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Idalopirdine"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Idalopirdine","otherNames":["Lu AE58054"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patient has a knowledgeable and reliable caregiver.\n* The patient is an outpatient.\n* The patient has probable AD.\n* The patient has mild to moderate AD.\n* Stable treatment with donepezil.\n* The patient, if a woman, must have had her last natural menstruation â‰¥24 months prior to baseline, OR be surgically sterile.\n* The patient, if a man, agrees to protocol-defined use of effective contraception if his female partner is of childbearing potential, OR must have been surgically sterilised prior to the screening visit.\n\nExclusion Criteria:\n\n* The patient has evidence of any clinically significant neurodegenerative disease, or other serious neurological disorders other than AD.\n* The patient has a Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) Axis I disorder other than AD.\n* The patient has evidence of clinically significant disease.\n* The patient's donepezil therapy is likely to be interrupted or discontinued during the study.\n* The patient is currently receiving memantine or has taken memantine within 2 months prior to screening.\n\nOther inclusion and exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Cognition","description":"Change from baseline to Week 24 in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) total score.\n\nThe Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-cog) is a 11-item neuropsychological test that assess the severity of cognitive impairment. The items determine the patient's orientation, memory, language, and praxis. Total score of the 11 items range from 0 to 70 (lower score indicates lower cognitive impairment).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.64","spread":"0.39"},{"groupId":"OG001","value":"0.55","spread":"0.39"},{"groupId":"OG002","value":"1.27","spread":"0.39"}]}]}]},{"type":"SECONDARY","title":"Change in Daily Functioning","description":"Change from baseline to Week 24 in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL23) total score.\n\nThe Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23) is a 23-item clinician-rated inventory to assess activities of daily living (conducted with a caregiver or informant). Each item comprises a series of hierarchical sub-questions, ranging from the highest level of independent performance to a complete loss for each activity. Total score of the 23 items ranges from 0 to 78 (higher score indicates lower disability).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.39","spread":"0.49"},{"groupId":"OG001","value":"-1.22","spread":"0.49"},{"groupId":"OG002","value":"-1.36","spread":"0.49"}]}]}]},{"type":"SECONDARY","title":"Change in Global Impression","description":"Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) score at Week 24.\n\nThe Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change is a semi-structured interview to assess clinically relevant changes in patients with AD. The items determine cognition, behavior, social and daily functioning. Severity at baseline is rated on a 7-point scale from 1 (normal, not ill at all) to 7 (among the most extremely ill patients). The clinically relevant change from baseline is rated on a 7-point scale from 1 (marked improvement) to 7 (marked worsening).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.30","spread":"0.06"},{"groupId":"OG001","value":"4.24","spread":"0.06"},{"groupId":"OG002","value":"4.35","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Change in Behavioural Disturbance","description":"Change from baseline to Week 24 in Neuropsychiatric Inventory (NPI) total score.\n\nThe Neuropsychiatric Inventory is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is rated for frequency (a 4-point scale from 1 \\[occasionally\\] to 4 \\[very frequent\\]) and severity (a 3-point scale from 1 \\[mild\\] to 3 \\[marked\\]). The total NPI score is the frequency ratings multiplied by the severity ratings and ranges from 0 to 144 (higher score indicates worse outcome).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.31","spread":"0.59"},{"groupId":"OG001","value":"-0.94","spread":"0.59"},{"groupId":"OG002","value":"-0.54","spread":"0.60"}]}]}]},{"type":"SECONDARY","title":"Change in Individual Behavioural Disturbance Items","description":"Change in single NPI item scores at Week 24.\n\nThe Neuropsychiatric Inventory is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is then rated for frequency (a 4-point scale from 1 \\[occasionally\\] to 4 \\[very frequent\\]) and severity (a 3-point scale from 1 \\[mild\\] to 3 \\[marked\\]). Total score for each single NPI item ranges from 0-12 (frequency multiplied by severity), where higher scores represent worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.08"},{"groupId":"OG001","value":"-0.18","spread":"0.08"},{"groupId":"OG002","value":"0.00","spread":"0.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.04"},{"groupId":"OG001","value":"-0.06","spread":"0.04"},{"groupId":"OG002","value":"-0.03","spread":"0.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.11"},{"groupId":"OG001","value":"-0.06","spread":"0.11"},{"groupId":"OG002","value":"-0.06","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"0.10"},{"groupId":"OG001","value":"-0.08","spread":"0.10"},{"groupId":"OG002","value":"-0.14","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.11"},{"groupId":"OG001","value":"-0.06","spread":"0.11"},{"groupId":"OG002","value":"-0.02","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.04"},{"groupId":"OG001","value":"-0.05","spread":"0.04"},{"groupId":"OG002","value":"-0.02","spread":"0.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.17"},{"groupId":"OG001","value":"-0.19","spread":"0.17"},{"groupId":"OG002","value":"-0.24","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.09"},{"groupId":"OG001","value":"-0.04","spread":"0.09"},{"groupId":"OG002","value":"0.02","spread":"0.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.12"},{"groupId":"OG001","value":"-0.05","spread":"0.12"},{"groupId":"OG002","value":"-0.17","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.14"},{"groupId":"OG001","value":"0.06","spread":"0.14"},{"groupId":"OG002","value":"0.12","spread":"0.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.12"},{"groupId":"OG001","value":"-0.07","spread":"0.12"},{"groupId":"OG002","value":"0.12","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"0.14"},{"groupId":"OG001","value":"-0.30","spread":"0.14"},{"groupId":"OG002","value":"-0.07","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"Change in NPI Anxiety Item Score in Patients With an NPI Anxiety Item Score of at Least 2 at Baseline","description":"Change from baseline to Week 24 in NPI anxiety item score in patients with an NPI anxiety item score of at least 2 at baseline\n\nThe Neuropsychiatric Inventory is a 12-item structured interview with a caregiver to assess behavioural disturbances. The NPI comprises 10 behavioural and 2 neurovegetative items. Each item consists of a screening question and several sub-questions that are rated no (not present) or yes (present). Each item is then rated for frequency (a 4-point scale from 1 \\[occasionally\\] to 4 \\[very frequent\\]) and severity (a 3-point scale from 1 \\[mild\\] to 3 \\[marked\\]). The total score for the NPI anxiety item ranges from 0-12 (frequency multiplied by severity), where a higher score represents a worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.48","spread":"0.38"},{"groupId":"OG001","value":"-1.82","spread":"0.40"},{"groupId":"OG002","value":"-1.69","spread":"0.40"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinical Improvement","description":"Clinical response at Week 24 (based on pre-specified ADAS-cog, ADCS-ADL23, and ADCS-CGIC changes \\[change in ADAS-cog below or equal to -4, change in ADCS-ADL23 at least 0, and ADCS-CGIC below or equal to 4\\])","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinical Worsening","description":"Clinical worsening at Week 24 (Based on pre-specified ADAS-cog, ADCS-ADL23, and ADCS-CGIC changes \\[change in ADAS-cog above or equal to 4, change in ADCS-ADL23 below 0, and ADCS-CGIC above 4\\])","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Cognitive Aspects of Mental Function","description":"Change from baseline to Week 24 in Mini Mental State Examination (MMSE). The Mini Mental State Examination (MMSE) is an 11-item test to assess the cognitive aspects of mental function. The subtests assess orientation, memory, attention, language, and visual construction. The scores for each item is dichotomous (1 = response is correct, 0 = response is incorrect). Total score of the 11 items ranges from 0 to 30 (higher score indicates lower deficit).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"0.21"},{"groupId":"OG001","value":"-0.45","spread":"0.21"},{"groupId":"OG002","value":"-0.34","spread":"0.21"}]}]}]},{"type":"SECONDARY","title":"Change in Health-related Quality of Life (EQ-5D) Utility Score","description":"Change from baseline to Week 24 in EuroQol 5-dimensional (EQ-5D) utility score\n\nThe EQ-5D is a patient-reported assessment that measures the patient's well-being. It consists of an utility score based on 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a Visual Analogue Scale (VAS). Each descriptive item is rated on a 3-point index ranging from 1 (no problems) to 3 (extreme problems) that is used for calculating a single summary index (from 0 to 1). A higher EQ-5D score indicates a worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.01"},{"groupId":"OG001","value":"0.02","spread":"0.01"},{"groupId":"OG002","value":"0.01","spread":"0.01"}]}]}]},{"type":"SECONDARY","title":"Change in Health-related Quality of Life (EQ-5D VAS)","description":"Change from baseline to Week 24 in EQ-5D Visual Analogue Scale (EQ-5D VAS).\n\nThe EQ-5D is a patient-reported assessment that measures the patient's well-being. It consists of an utility score based on 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a Visual Analogue Scale (VAS). The VAS ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.35","spread":"0.99"},{"groupId":"OG001","value":"1.87","spread":"0.99"},{"groupId":"OG002","value":"1.00","spread":"1.01"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":282},"commonTop":["Accidental overdose"]}}}